Crossmark

A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus

Published Online: 2021-06-03

Authors

Kiruthika, S.

Bhat, Ruchika

Dash, Rozaleen

Rathore, Anurag S.

Vivekanandan, Perumal

Jayaram, B.
License Information

Text and Data Mining valid from 2021-06-03

Version of Record valid from 2021-06-03
More Information

Article History

Received: 2 March 2021

Accepted: 19 May 2021

First Online: 3 June 2021

Competing interests

: The authors declare no competing interests.

Document is current